Arcturus Therapeutics stock price falls as MACD and KDJ indicators show death cross.
ByAinvest
Tuesday, Jul 29, 2025 9:50 am ET1min read
ARCT--
Despite the technical indicators pointing to a potential decline, analysts remain largely bullish on ARCT. According to TipRanks, 9 out of 9 analysts have given ARCT a Strong Buy rating in the past three months, with an average 12-month price target of $63.50, representing a 325.03% upside from the current price of $14.94 [1].
The analysts' optimism is driven by several factors, including promising mRNA developments and strategic advancements in vaccine development. For instance, Piper Sandler's Yasmeen Rahimi has reiterated a Buy rating with an 837.08% upside, citing the company's high potential in mRNA technology [2]. Similarly, William Blair's Myles Minter has reaffirmed their Buy rating, highlighting the competitive edge in urea-cycle disorders [3].
However, the overall financial health of ARCT is a concern. The company has been facing declining revenues and cash flow issues, which have weighed heavily on its valuation and financial stability [4]. The current earnings estimate for the next quarter is -$0.90, with a range of -$1.76 to -$0.34, indicating a potential for continued financial strain [5].
In conclusion, while analysts remain optimistic about ARCT's long-term prospects, the recent technical indicators suggest a potential short-term decline in stock price. Investors should closely monitor the company's financial health and the impact of its ongoing developments on its stock performance.
References:
[1] https://www.tipranks.com/stocks/arct/forecast
[2] https://www.tipranks.com/stocks/arct/forecast
[3] https://www.tipranks.com/stocks/arct/forecast
[4] https://www.tipranks.com/stocks/arct/forecast
[5] https://www.tipranks.com/stocks/arct/forecast
PIPR--
Arcturus Therapeutics' 15-minute chart has recently triggered a MACD Death Cross and KDJ Death Cross at 09:45 on July 29, 2025. This technical indicator suggests that the stock price has the potential to continue declining, and the momentum of the stock price is shifting towards the downside, with a potential for further decreases in value.
Arcturus Therapeutics (ARCT) has recently experienced a technical downturn, with both the MACD and KDJ indicators triggering death crosses at 09:45 on July 29, 2025. This suggests that the stock price may continue to decline and that the momentum is shifting towards the downside, potentially leading to further decreases in value.Despite the technical indicators pointing to a potential decline, analysts remain largely bullish on ARCT. According to TipRanks, 9 out of 9 analysts have given ARCT a Strong Buy rating in the past three months, with an average 12-month price target of $63.50, representing a 325.03% upside from the current price of $14.94 [1].
The analysts' optimism is driven by several factors, including promising mRNA developments and strategic advancements in vaccine development. For instance, Piper Sandler's Yasmeen Rahimi has reiterated a Buy rating with an 837.08% upside, citing the company's high potential in mRNA technology [2]. Similarly, William Blair's Myles Minter has reaffirmed their Buy rating, highlighting the competitive edge in urea-cycle disorders [3].
However, the overall financial health of ARCT is a concern. The company has been facing declining revenues and cash flow issues, which have weighed heavily on its valuation and financial stability [4]. The current earnings estimate for the next quarter is -$0.90, with a range of -$1.76 to -$0.34, indicating a potential for continued financial strain [5].
In conclusion, while analysts remain optimistic about ARCT's long-term prospects, the recent technical indicators suggest a potential short-term decline in stock price. Investors should closely monitor the company's financial health and the impact of its ongoing developments on its stock performance.
References:
[1] https://www.tipranks.com/stocks/arct/forecast
[2] https://www.tipranks.com/stocks/arct/forecast
[3] https://www.tipranks.com/stocks/arct/forecast
[4] https://www.tipranks.com/stocks/arct/forecast
[5] https://www.tipranks.com/stocks/arct/forecast
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet